Fisher Asset Management LLC Sells 17,236 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Fisher Asset Management LLC decreased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.6% in the 4th quarter, HoldingsChannel reports. The firm owned 288,693 shares of the medical instruments supplier’s stock after selling 17,236 shares during the quarter. Fisher Asset Management LLC’s holdings in OraSure Technologies were worth $2,367,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OSUR. Allspring Global Investments Holdings LLC raised its holdings in shares of OraSure Technologies by 421.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 384,439 shares of the medical instruments supplier’s stock worth $2,280,000 after buying an additional 310,715 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of OraSure Technologies by 122.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock worth $19,707,000 after acquiring an additional 1,323,197 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of OraSure Technologies by 3.1% in the 3rd quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after purchasing an additional 5,875 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of OraSure Technologies by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after purchasing an additional 64,367 shares in the last quarter. Finally, Aviva PLC bought a new stake in shares of OraSure Technologies during the 3rd quarter valued at approximately $580,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Stock Down 4.2 %

NASDAQ OSUR opened at $5.31 on Thursday. The company has a market capitalization of $406.27 million, a price-to-earnings ratio of 7.38 and a beta of 0.23. OraSure Technologies, Inc. has a twelve month low of $4.38 and a twelve month high of $8.45. The stock has a fifty day simple moving average of $6.07 and a 200 day simple moving average of $6.80.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company had revenue of $75.88 million for the quarter, compared to analyst estimates of $74.13 million. During the same period in the previous year, the firm earned $0.21 earnings per share. The firm’s quarterly revenue was down 38.3% on a year-over-year basis. Research analysts expect that OraSure Technologies, Inc. will post -0.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on OSUR shares. Evercore ISI cut their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. StockNews.com upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.